Recent developments in U.S.-China biotechnology relations highlight growing tensions. John Moolenaar, chairman of the U.S. House Select Committee on China, has urged the Treasury Secretary to restrict biotechnology investments in China, citing a significant partnership between U.S.-based Bristol Myers Squibb and China’s Hengrui Pharma. Despite efforts to impose such restrictions, the Chinese biotech sector continues to thrive, with out-licensing deals reaching $136 billion in 2025 and rapid advancements in technology attracting global investors. Notably, recent collaborations, such as a licensing deal between Pfizer and Innovent Biologics valued at $10.5 billion, demonstrate ongoing engagement between U.S. and Chinese companies, indicating that restrictions may not halt cooperation vital for global health advancements.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.stdaily.com/web/English/2026-06/15/content_532271.html
